Myeloma

A Phase 1 clinical trial that uses the gene editing tool CRISPR to engineer multiple myeloma cellular immunotherapy will soon be underway at the…

The U.S. Food and Drug Admnistration will give priority review to Darzalex (daratumumab) as an add-on to standard treatments for multiple myeloma patients who cannot…

A single injection of a new drug combination leads to faster and more effective harvesting of blood stem cells from bone marrow donors, a new mouse…

The first patient has been dosed in a Phase 1 trial of P-BCMA-101, a new, more powerful type of CAR T-cell therapy to fight multiple…

Gamida Cell is enrolling participants in a Phase 1 clinical trial of an immunotherapy for myeloma and non-Hodgkin’s lymphoma that is based on expanding the…

Molecular Partners‘ multiple myeloma treatment candidate MP0250 showed positive preliminary safety and effectiveness results in an ongoing Phase 2 clinical study, according to the biopharmaceutical…

Patients with relapsed or refractory multiple myeloma who are treated with new therapy combinations remain on their treatments far shorter than those participating in clinical…

Newly diagnosed multiple myeloma patients respond better to treatment when Empliciti (elotuzumab) is added to a combination of Revlimid (lenalidomide) and dexamethasone,…

The U.S. Food and Drug Administration (FDA) has agreed to extend Xgeva‘s (denosumab) approval to include patients with multiple myeloma who have bone lesions. The…

A preclinical study has shown that a new dual-targeting APRIL CAR T-cell therapy appears to be better at eliminating multiple myeloma cells than conventional CAR T-cell…